(Q61613759)
Statements
Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome (English)
Paul Abrams
Dzelal Serdarevic
Katherine Hargreaves
Vikram Khullar
1032 Study Group